Tuesday, January 21, 2020


SVRA Savara Inc. gains 197% Jan 21, 2020

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for serious or life-threatening diseases with significant unmet needs. Its lead product candidate is AIR001, a sodium nitrite solution for inhalation through nebulization, which is in Phase II clinical stage for the treatment of heart failure with preserved ejection fraction, as well as in Phase I/II study in patients with cystic fibrosis. The company was formerly known as ADVENTRX Pharmaceuticals, Inc. and changed its name to Mast Therapeutics, Inc. in March 2013. Mast Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive